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Abstract
Background: Human myelogenous leukemia characterized by either the non random t(8; 21)(q22;
q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical
features. Some of these features could be consequent to differential epigenetic transcriptional
deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins
deriving from the two translocations. Preliminary findings showing that these fusion proteins lead
to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes,
would support this hypothesis. Here we show that combining conventional global gene expression
arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an
effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by
the leukemia-associated AML1-MTG16 protein.
Results: We interrogated mouse gene expression microarrays with probes generated either from
32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte
differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF),
or from 32D cells infected with the cognate empty vector. From the analysis of differential gene
expression alone (using as criteria a p value < 0.01 and an absolute fold change > 3), we were unable
to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1
targets. However, when we applied a bioinformatic approach to search for AML1-consensus
sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct
AML1 targets. By focusing on the most significantly downregulated genes, we found that both the
AML1-consensus and the transcription start site chromatin regions were significantly marked by
aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing
a CpG island, was aberrantly methylated.
Conclusion: This study shows that a leukemia-associated fusion protein can impose a distinct
epigenetic repressive signature at specific sites in the genome. These findings strengthen the
conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes.
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Nuclear hormone receptors and transcription factors can
regulate the transcription of their target genes by inducing
chromatin changes. Paradigmatic are the retinoic acid
receptor alpha (RARα) and the transcription factor core
binding factor (CBF), which regulate in this way the tran-
scription of target genes involved in hematopoietic proc-
esses [1,2]. Differently from RARα, which epigenetically
activates its targets by recruiting coactivator protein com-
plexes with histone acetyl transferase (HAT) activity only
when bound to retinoic acid, CBF can directly recruit
HAT-containing complexes to activate its targets [3-6].
One of the two CBF subunits, CBFα or AML1, can bind
target genes endowed with the AML1-consensus sequence
TG(T/C)GGT via its N-terminal DNA-binding domain [7].
AML1, encoding a master hematopoietic transcription fac-
tor, is frequently affected by different chromosome trans-
locations in leukemic cells [8]. Moreover, AML1
haploinsufficiency was found to be associated with famil-
ial platelet disorder, a condition predisposing to acute
myeloid leukemia [9].
Two leukemia-associated chromosome translocations, the
t(8;21)(q22;q22) and the t(16;21)(q24;q22), result in the
fusion between the N-terminal region of AML1 and the C-
terminal regions of two almost identical chromatin core-
pressors, MTG8 and MTG16, leading to the formation of
AML1-MTG8 and AML1-MTG16, respectively [10-13].
Upon fusion with either MTG8 or MTG16, AML1 is con-
verted from a transcriptional activator into a transcrip-
tional repressor of AML1-targets. Specific MTG domains
in the wild type, as well as in the MTG fusion proteins, can
interact, directly or via other corepressors such as NCoR
and Sin3A, with histone deacetylases (HDACs), thus cre-
ating a repressive chromatin state at AML1 target sites
(reviewed in [14,15]). Repression at these sites is further
enhanced by the formation of oligomers between the
fusion proteins and wild-type MTG proteins [16-18].
Myeloid cell differentiation systems, such as the 32D
mouse myeloid cell line, ectopically expressing either
AML1-MTG8 or AML1-MTG16, were used as models to
simulate some of the effects of these fusion proteins in
myelogenesis and leukemogenesis. Both fusion proteins,
when exogenously expressed in the 32D background,
were shown to affect granulocytic differentiation and pro-
duce distinct effects on cell proliferation [19-21]. In a pre-
liminary study, we found that AML1-MTG16, when
exogenously expressed in 32D cells, can induce aberrant
myeloid phenotypes in association with repressive modi-
fications at the chromatin of the Colony stimulating fac-
tor 1 receptor (Csf1r), an AML1-target gene encoding the
macrophage colony stimulating factor receptor [19].
Based on this finding, we hypothesize that the compara-
tive epigenetic analysis of the changes induced by differ-
ent AML1-MTG fusion proteins in an identical cell context
(e.g. the 32D context) might provide a lead to elucidating
the differences observed in leukemic cells carrying either
one of the two proteins [8]. The objective of this study was
to demonstrate whether AML1-MTG16 induces epigenetic
changes at AML1-target genes in the 32D myeloid cell
genome. Only by coupling global gene expression array
analysis with a bioinformatic genomic survey for the
AML1-consensus sequence, we were able to close onto
AML1-targets downregulated by AML1-MTG16. AML1-
MTG16-induced transcriptional downregulation was
marked by the acquisition of a distinct repressive chroma-
tin signature.
Results
Global gene expression array analysis of AML1-MTG16-
expressing cells
To study the molecular and biological consequences of
AML1-MTG16 expression in a myeloid differentiation cell
model, we previously developed, by infecting 32D mouse
myeloblasts with retroviral particles carrying either the
pLNCX2 vector containing the AML1-MTG16 cDNA or
the cognate empty vector, stable independent clones
expressing AML1-MTG16 (hereafter called A16 clones)
and stable independent control clones (hereafter called
"mock" clones), respectively (Figure 1A). Upon treatment
with granulocyte colony stimulating factor (G-CSF), A16
clones do not undergo granulocytic differentiation and
proliferate significantly less than mock clones (Figure 1B).
Global gene expression analysis (setting the p-value at <
0.05 and the absolute fold change at > 1.5) of a prototypic
A16 clone and a prototypic mock clone grown either with
interleukin 3 (IL-3) or G-CSF for 16 h, was combined with
bioinformatic analysis of the proteins encoded by all the
differentially expressed genes with the Ingenuity software
(see Methods). This analysis clearly revealed a network
comprising proteins critical for platelet function in A16
cells (see Additional file 1). The identification of this pro-
tein network strongly supports the biological data, indi-
cating the occurrence of functional AML1
haploinsufficiency in A16 cells [9].
Further analysis of the gene expression data (setting the p-
value at < 0.01 and the absolute fold change at > 3) ena-
bled us to identify 138 differentially expressed genes, of
which 66 differentially expressed genes in cells grown
with IL-3, 67 differentially expressed genes in cells grown
with G-CSF, and 5 differentially expressed genes in both
cells grown with IL-3 and G-CSF (Figure 1C, left, and
Table 1 and Table 2). According to the Ingenuity software,
the differentially expressed genes in A16 cells were mostly
implicated in tumorigenesis, cell proliferation, and
hematopoiesis (Figure 1C, right). Since from this analysis
alone we were unable to conclude whether, or not, these
genes were AML1-MTG16 direct targets, we devised a bio-Page 2 of 16
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sensus sequence in the 10 Kb region around the
transcription start site of these genes.
Identification of genes containing the AML1-consensus 
sequence by bioinformatic analysis
Since the AML1-MTG proteins have a transcriptionally
repressive function (reviewed in [14]), we focused our
bioinformatic analysis on the 37 genes downregulated by
AML1-MTG16 (see genes in bold in Table 1 and Table 2).
Specifically, we searched the 10 Kb around the transcrip-
tion start site of each gene for either the AML1-binding
consensus sequence TG(T/C)GGT or, this sequence in
reverse orientation, ACC(G/A)CA. With the MEME soft-
ware (see Methods) we identified a conserved motif, here-
after called AML1-consensus motif (Figure 2A),
encompassing the AML1-consensus sequence in seven-
teen out of the 37 genes (Figure 2B and Table 3). We
Global gene expression analysis of AML1-MTG16-expressing cellsFigure 1
Global gene expression analysis of AML1-MTG16-expressing cells. A. The 32D cell model, comprising clones 
expressing the AML1-MTG16 protein (A16 clones) and control clones ("mock" clones), which do not express the fusion pro-
tein. B. A16 clones, differently from mock clones, do not undergo granulocytic differentiation and display an impaired prolifer-
ation in the presence of G-CSF. C. Most of the genes whose expression is significantly affected in A16 cells were found 
previously implicated in biological processes.Page 3 of 16
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nce of IL-3.
/Ingenuity annotations Fold change
egulation of transcription 16.4
kinase signaling pathway 15.9
electron transport 12.9
l adhesion/cell proliferation 9.6
immune response 8.6
--- 7.4
proteolysis 7.2
--- 6.4
egulation of transcription 6.3
egulation of transcription 6.2
electron transport 6.1
-protein signaling pathway 6.0
physiological processes 6.0
--- 5.9
egulation of transcription 5.8
electron transport 5.8
signal transduction 5.8
protein folding 5.7
--- 5.7
 hydrolysis/proton transport 5.6
immune response 5.5
organization/transcriptional regulation 5.4
mRNA splicing 5.0
-protein signaling pathway 4.9
cell adhesion 4.9
vision 4.8
--- 4.7
vision 4.7
protein transport 4.4
ion transport 4.4
cell proliferation 4.4
apoptosis 4.2
egulation of transcription 4.2
--- 3.9
ion transport 3.7
-protein signaling pathway 3.7
defense response 3.5
cell adhesion 3.4
complement activation 3.4
egulation of transcription 3.4
ropeptide signaling pathway 3.4
protein transport 3.3
racellular signaling cascade 3.3
blood coagulation 3.2B
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Table 1: Selection of genes differentially expressed in AML1-MTG16-positive cells versus AML1-MTG16-negative cells grown in the prese
Affymetrix ID NCBI acc. number Gene Symbol Gene Title GO
1450042_at BB322201 Arx aristaless related homeobox gene (Drosophila) r
1460300_a_at NM_008523 Ltk leukocyte tyrosine kinase
1423869_s_at AF349659 Txnrd3 thioredoxin reductase 3
1418796_at NM_009131 Scgf stem cell growth factor cel
1427329_a_at AI326478 Igh-6 immunoglobulin heavy chain 6 (heavy chain of IgM)
1418588_at NM_009513 Vmp vesicular membrain protein p24
1450652_at NM_007802 Ctsk cathepsin K
1428439_at BG066220 Nyren18-pending NY-REN-18 antigen
1419416_a_at NM_011244 Rarg retinoic acid receptor, gamma r
1426800_at BM214169 D330025I23Rik (Cbfb) RIKEN cDNA D330025I23 gene (core-binding factor beta subunit) r
1419136_at NM_134066 Akr1c18 aldo-keto reductase family 1, member C18
1425432_at AF260307 Oprm opioid receptor, mu G
1418346_at NM_013754 Insl6 insulin-like 6
1449426_a_at NM_011922 Anxa10 annexin A10
1423029_at NM_008236 Hes2 hairy and enhancer of split 2 (Drosophila) r
1454007_a_at AK020384 Zfp142 zinc finger protein 142
1423313_at BG070255 Pde7a phosphodiesterase 7A
1451915_at L20509 Cct3 chaperonin subunit 3 (gamma)
1452487_x_at BB133664 Pirb paired-Ig-like receptor B
1422030_at AF326316 Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A isoform 4 ATP
1427753_at Z95479 Igh-4 immunoglobulin heavy chain 4 (serum IgG1)
1437235_x_at BB218844 Lpp LIM domain containing preferred translocation partner in lipoma cytoskeleton 
1426938_at BB627486 Nova1 neuro-oncological ventral antigen 1
1460416_s_at M55219 Csprs component of Sp100-rs G
1427884_at AW550625 Col3a1 procollagen, type III, alpha 1
1450453_a_at NM_012065 Pde6g phosphodiesterase 6G, cGMP-specific, rod, gamma
1455957_x_at AV034167 Ceacam11 CEA-related cell adhesion molecule 11
1450215_at NM_009038 Rcvrn recoverin
1452489_at BC016258 Vps11 vacuolar protein sorting 11 (yeast)
1421705_at NM_018732 Scn3a sodium channel, voltage-gated, type III, alpha polypeptide
1421375_a_at NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin)
1433658_x_at AV300794 Pcbp4 poly(rC) binding protein 4
1418136_at NM_009365 Tgfb1i1 transforming growth factor beta 1 induced transcript 1 r
1450629_at AV114522 Eplin-pending epithelial protein lost in neoplasm
1455421_x_at AW490145 Clcn1 chloride channel 1
1418451_at BB522409 Gng2 guanine nucleotide binding protein (G protein), gamma 2 subunit G
1450709_at NM_007851 Defcr5 defensin related cryptdin 5
1423561_at AI838010 Nell2 nel-like 2 homolog (chicken)
1452279_at BB800282 Pfc properdin factor, complement
1424531_a_at BC010807 Tcea3 transcription elongation factor A (SII), 3 r
1419325_at NM_019515 Nmu neuromedin neu
1422945_a_at AI844677 Kif5c kinesin family member 5C
1460280_at NM_010815 Mona monocytic adaptor int
1448529_at NM_009378 Thbd thrombomodulin
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--- 3.2
gnaling pathway/cell proliferation 3.2
amino acid transport 3.2
egulation of transcription 3.1
n-dependent protein catabolism 3.1
sory perception/G-protein signaling 
pathway
3.0
--- -3.0
gulation of transcription -3.0
--- -3.1
apoptosis -3.1
structural function -3.3
cell proliferation -3.6
--- -3.7
immune response? -3.7
ion transport -3.8
--- -4.0
toskeleton organization -4.3
--- -4.4
apoptosis -4.6
hematopoiesis -4.7
phatase signaling pathway -4.8
synaptic transmission -4.8
DNA repair -8.2
agulation/G-protein signaling 
pathway
-14.2
hromatin remodeling? -16.9
phatase signaling pathway -17.7
signal transduction -27.2
nce of IL-3. (Continued)B
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1449830_at NM_013766 Prlpi prolactin-like protein I
1423596_at BB528391 Nek6 NIMA (never in mitosis gene a)-related expressed kinase 6 kinase si
1450435_at NM_008478 Slc7a2 solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2
1420373_at BI249549 Foxj2 forkhead box J2 r
1436769_at AV101011 Psma1 proteasome (prosome, macropain) subunit, alpha type 1 ubiquiti
1421778_at NM_011911 V1rb2 vomeronasal 1, receptor B2 chemosen
1448416_at NM_008597 Mglap matrix gamma-carboxyglutamate (gla) protein
1419012_at NM_011766 Zfpm2 zinc finger protein, multitype 2 re
1449833_at NM_011472 Sprr2f small proline-rich protein 2F
1424814_a_at BC025541 9030625M01Rik 
(Bclg)
RIKEN cDNA 9030625M01 gene (apoptosis regulator 
Bclg)
1417338_at U03487 Epb4.2 erythrocyte protein band 4.2
1448152_at NM_010514 Igf2 insulin-like growth factor 2
1429947_a_at AK008179 Zbp1 Z-DNA binding protein 1
1420394_s_at U05264 Gp49b glycoprotein 49 B
1424898_at BC021154 Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter 
family), member 1
1416822_at BC013711 Es2el expressed sequence 2 embryonic lethal
1420779_at NM_010213 Fhl3 four and a half LIM domains 3 cy
1419124_at NM_133829 AW212394 expressed sequence AW212394
1425597_a_at AW060288 Qk quaking
1422416_s_at NM_016983 Vpreb2 Pre-B lymphocyte gene 2
1425863_a_at AF295638 Ptpro protein tyrosine phosphatase, receptor type, O phos
1418177_at AF233778 Gabrg2 gamma-aminobutyric acid (GABA-A) receptor, subunit 
gamma 2
1421309_at NM_008598 Mgmt O-6-methylguanine-DNA methyltransferase
1421288_at NM_007975 F2rl3 coagulation factor II (thrombin) receptor-like 3 blood co
1449347_a_at NM_021365 Xlr4 X-linked lymphocyte-regulated 4 c
1448511_at NM_016933 Ptprcap protein tyrosine phosphatase, receptor type, C 
polypeptide-associated protein
phos
1421775_at NM_010184 Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide
Limits: p-value < 0.01; absolute fold change > 3.
In bold are the AML1-MTG16-downregulated genes searched for AML1-consensus motifs.
Table 1: Selection of genes differentially expressed in AML1-MTG16-positive cells versus AML1-MTG16-negative cells grown in the prese
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ingenuity annotations Fold change
ase signaling pathway 24.5
ase signaling pathway 19.9
teolysis/cell migration 17.7
ration/complement activation 14.7
ellular signaling cascade 10.4
cell proliferation 10.2
nsduction/cell proliferation 9.5
lation of transcription 8.8
cell adhesion 8.6
l transduction/apoptosis 6.7
--- 6.4
ellular junction assembly 6.1
cell proliferation 5.9
cell adhesion 5.5
metabolism 5.5
differentiation/corepressor 5.5
sperm motility 5.4
--- 5.2
ion transport 5.1
ino acid metabolism 5.1
lation of transcription 5.0
lation of transcription 4.9
lation of transcription 4.8
skeleton organization 4.8
cell adhesion 4.8
cell adhesion 4.7
--- 4.7
cell proliferation 4.5
ellular signaling cascade 4.4
lation of transcription 4.3
ion of transcription/signal 
transduction
4.2
ir/regulation of transcription/
apoptosis
4.2
--- 4.2
metabolism 4.1
rrest///programmed cell death 4.0
--- 4.0
immune response 4.0
signal transduction 3.9
--- 3.9
sion/complement activation 3.9
cell adhesion 3.9B
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Table 2: Selection of genes differentially expressed in AML1-MTG16-positive cells versus AML1-MTG16-negative cells grown in the presen
Affymetrix ID NCBI acc. number Gene Symbol Gene Title GO/I
1437100_x_at BB206220 Pim3 proviral integration site 3 kin
1460300_a_at NM_008523 Ltk leukocyte tyrosine kinase kin
1416257_at NM_009794 Capn2 calpain 2 pro
1417314_at NM_008198 H2-Bf histocompatibility 2, complement component factor B cell prolife
1425380_at AF331457 Rasgrp4 RAS guanyl releasing protein 4 intrac
1450322_s_at NM_011409 Slfn3 schlafen 3
1421793_at NM_010198 Fgf11 fibroblast growth factor 11 signal tra
1420348_at NM_008499 Lhx5 LIM homeobox protein 5 regu
1419605_at NM_010796 Mgl1 macrophage galactose N-acetyl-galactosamine specific lectin 1
1420360_at NM_010051 Dkk1 dickkopf homolog 1 (Xenopus laevis) signa
1425647_at BG069740 Rnf33 ring finger protein 33
1434851_s_at AU015319 Crb3 crumbs homolog 3 (Drosophila) interc
1427102_at AF099975 Slfn4 schlafen 4
1437218_at BM234360 Fn1 fibronectin 1
1417777_at BC014865 Ltb4dh leukotriene B4 12-hydroxydehydrogenase
1419406_a_at NM_016707 Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) T/B-cell 
1418358_at NM_008574 Mcsp mitochondrial capsule selenoprotein
1450499_at NM_009124 Sca1 spinocerebellar ataxia 1 homolog (human)
1418257_at BB732135 Slc12a7 solute carrier family 12, member 7
1424744_at BC021950 Sds serine dehydratase am
1456305_x_at BB702568 Obox1 oocyte specific homeobox 1 regu
1449707_at C80272 Nr5a2 nuclear receptor subfamily 5, group A, member 2 regu
1421504_at NM_009239 Sp4 trans-acting transcription factor 4 regu
1427079_at U51204 Mapre3 microtubule-associated protein, RP/EB family, member 3 cyto
1429626_at AV024301 Sftpa surfactant associated protein A
1452793_at AI509011 Cldn10 claudin 10
1419507_at NM_013713 Krtap15 keratin associated protein 15
1421375_a_at NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin)
1419517_at NM_028408 2900075G08Rik RIKEN cDNA 2900075G08 gene intrac
1454736_at BM119297 4921515A04Rik RIKEN cDNA 4921515A04 gene regu
1436244_a_at AU067681 Tle2 transducin-like enhancer of split 2, homolog of Drosophila E(spl) regulat
1420594_at NM_007525 Bard1 BRCA1 associated RING domain 1 DNA repa
1426093_at AF220141 Trim34 tripartite motif protein 34
1424748_at BC021504 Galnt11 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 11
1416855_at BB550400 Gas1 growth arrest specific 1 cell cycle a
1422310_at NM_009223 Snn stannin
1452463_x_at BG966217 Igk-V8 immunoglobulin kappa chain variable 8 (V8)
1450415_at NM_008805 Pde6a phosphodiesterase 6A, cGMP-specific, rod, alpha
1418792_at AF326561 Sh3gl2 SH3-domain GRB2-like 2
1451759_at BC013893 Masp2 mannan-binding lectin serine protease 2 cell adhe
1418921_at AY059393 Necl1-pending nectin-lke 1
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1416188_at BC004651 Gm2a GM2 ganglioside activator protein sp
1448392_at NM_009242 Sparc secreted acidic cysteine rich glycoprotein
1419485_at BB759833 Foxc1 forkhead box C1 reg
1419602_at NM_010451 Hoxa2 homeo box A2 reg
1427358_a_at BC026671 Dapk1 death associated protein kinase 1
1450827_at NM_024245 Kif23 kinesin family member 23
1421280_at Z36357 Gabra1 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 1 s
1452279_at BB800282 Pfc properdin factor, complement c
1415854_at BB815530 Kitl kit ligand cell p
1417513_at AI255184 Evi5 ecotropic viral integration site 5
1431379_a_at AK005153 Slc13a1 solute carrier family 13 (sodium/sulphate symporters), member 1
1418476_at NM_018827 Crlf1 cytokine receptor-like factor 1
1416009_at NM_019793 Tm4sf8-pending transmembrane 4 superfamily member 8 signal tr
1451633_a_at BC025929 Gng1 guanine nucleotide binding protein (G protein), gamma 1 
subunit
G-pro
1425978_at AF384055 Srfcp-pending SRF co-factor protein (cardiac and smooth muscle) regulatio
regula
1425153_at BC008538 Myh2 myosin, heavy polypeptide 2, skeletal muscle, adult cyto
1448755_at AF011450 Col15a1 procollagen, type XV
1433888_at AV343478 Atp2b2 ATPase, Ca++ transporting, plasma membrane 2
1426868_x_at AK003174 Lmna lamin A
1423292_a_at BG072867 Prx periaxin intrace
1449891_a_at NM_028523 Esdn-pending endothelial and smooth muscle cell-derived neuropilin-like 
molecule
1425708_at AF285585 Rnf17 ring finger protein 17
1449836_x_at NM_007546 Biklk Bcl2-interacting killer-like
1448710_at D87747 Cxcr4 chemokine (C-X-C motif) receptor 4 defense
1419227_at NM_009839 Cct6b chaperonin subunit 6b (zeta)
1455853_x_at BB768303 2700085A14Rik 
(Sas)
RIKEN cDNA 2700085A14 gene (Sarcoma amplified 
sequence)
cell prolif
1416822_at BC013711 Es2el expressed sequence 2 embryonic lethal
1422473_at BM246564 Pde4b phosphodiesterase 4B, cAMP specific s
1418499_a_at NM_020574 Kcne3 potassium voltage-gated channel, Isk-related subfamily, 
gene 3
1419537_at NM_031198 Tcfec transcription factor EC regu
1449347_a_at NM_021365 Xlr4 X-linked lymphocyte-regulated 4 chr
Limits: p-value < 0.01; absolute fold change > 3.
In bold are the AML1-MTG16-downregulated genes searched for AML1-consensus motifs.
Table 2: Selection of genes differentially expressed in AML1-MTG16-positive cells versus AML1-MTG16-negative cells grown in the prese
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38focused on five of these genes, Fcer1a, Tcfec, Ptprcap, F2rl3,
and Mgmt (Figure 2B, right), because they were among the
most significantly downregulated genes. Fcer1a, Tcfec,
Ptprcap, F2rl3, and Mgmt encode for known proteins. Spe-
cifically, Fcer1a is the Fc fragment of IgE and is involved in
the immune response [22]; Tcfec is a transcription factor
that induces, among other genes, the G-CSF receptor gene
[23,24]; Ptprcap is a transmembrane protein associated
with CD45, a key regulator of lymphocytes activation
[25]; F2rl3 is a member of G protein-coupled protease-
activated receptors (PARs) of the coagulation factor II
(thrombin) and plays an important role in platelet activa-
tion [26]; Mgmt is a DNA repair enzyme that is frequently
lost in cancer due to epigenetic silencing [27]. Downregu-
lation of these genes was confirmed by real time RT-PCR
(Figure 2C).
Fcer1a, Tcfec, Ptprcap, F2rl3, and Mgmt are direct 
AML1-MTG16 targets
Quantitative chromatin immunoprecipitation (ChIP)
with an anti-AML1 specific antibody, but not with an anti-
MTG16 antibody (data not shown), showed significant (p
< 0.05) enrichment of the region encompassing the
AML1-consensus motif (see bars in figure 3A, left) relative
to an arbitrary control region without the AML1-consen-
sus motif in the mock clone chromatin for all five genes,
indicating endogenous AML1 binding at these regions
(Figure 3B). ChIP with an anti-MTG16 antibody showed
instead a significant enrichment of exogenous AML1-
MTG16 in the same chromatin regions in the A16 clones
(Figure 3B). The human homologues of these genes also
contain an AML1-consensus sequence(s) in the 10Kb
region surrounding the transcription start site, pointing to
AML1-MTG16-induced downregulation of putative AML1-targetsFigure 2
AML1-MTG16-induced downregulation of putative AML1-targets. A. The AML1-consensus motif, containing the 
AML1-consensus sequence (framed), found by bioinformatic analysis of the genes significantly downregulated in A16 cells. The 
height of the columns associated with each nucleotide is proportional to the conservation level. The "logo" representation of 
the motif instead indicates in which proportion the single bases are present at each position. B. Seventeen out of the 37 down-
regulated genes are putative AML1-targets. The fold-changes of five of the most significantly downregulated genes are reported 
at right. C. Real time RT-PCR confirmed the significant (p < 0.01) downregulation of the five genes.Page 8 of 16
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Table 3: Selection of putative AML1-target genes downregulated in AML1-MTG16-positive cells versus AML1-MTG16-negative cells.
Affymetrix ID NCBI acc. number Gene Symbol Gene Title GO/Ingenuity annotations Fold change IL-3 Fold change G-CSF
1417338_at U03487 Epb4.2 erythrocyte protein band 4.2 structural function -3.3 ---
1433888_at AV343478 Atp2b2 ATPase, Ca++ transporting, plasma membrane 2 metabolism --- -3.5
1426868_x_at AK003174 Lmna lamin A cell morphology --- -3.5
1423292_a_at BG072867 Prx periaxin intracellular signaling cascade --- -3.6
1449891_a_at NM_028523 Esdn-pending endothelial and smooth muscle cell-derived 
neuropilin-like molecule
--- --- -3.6
1425708_at AF285585 Rnf17 ring finger protein 17 --- --- -4.2
1419124_at NM_133829 AW212394 expressed sequence AW212394 --- -4.4 ---
1425597_a_at AW060288 Qk quaking apoptosis -4.6 ---
1419227_at NM_009839 Cct6b chaperonin subunit 6b (zeta) protein folding --- -5.0
1455853_x_at BB768303 2700085A14Rik (Sas) RIKEN cDNA 2700085A14 gene (Sarcoma 
amplified sequence)
cell proliferation/signal transduction --- -5.3
1422473_at BM246564 Pde4b phosphodiesterase 4B, cAMP specific signal transduction --- -7.8
1421309_at NM_008598 Mgmt O-6-methylguanine-DNA methyltransferase DNA repair -8.2 ---
1421288_at NM_007975 F2rl3 coagulation factor II (thrombin) receptor-like 3 blood coagulation/G-protein signaling 
pathway
-14.2 ---
1449347_a_at NM_021365 Xlr4 X-linked lymphocyte-regulated 4 chromatin remodelling? -16.9 -34.4
1448511_at NM_016933 Ptprcap (1) protein tyrosine phosphatase, receptor type, C 
polypeptide-associated protein
phosphatase signaling pathway -17.7 ---
1419537_at NM_031198 Tcfec transcription factor EC regulation of transcription --- -20.6
1421775_at NM_010184 Fcer1a Fc receptor, IgE, high affinity I, alpha polypeptide signal transduction -27.2 ---
Motif conservation significance: p < 10E-5.
(1) The Ptprcap AML1-consensus motif is located in an intron of a 5' adjacent gene (Coro1b).
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38
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AML1-target gene validationFigure 3
AML1-target gene validation. A. Relative position of the AML1-consensus motifs (left) and their sequence (right) in the 
five putative AML1-target genes that were analyzed by ChIP. B. Quantitative ChIP analysis with antibodies either against AML1 
or MTG16 showing a significant (p < 0.05) enrichment of chromatin containing AML1-consensus motifs vs. chromatin contain-
ing a control region in AML1-MTG16-negative and AML1-MTG16-positive cells, respectively.
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38these five genes as novel, bona fide direct AML1-targets
genes.
Repressive chromatin changes at AML1-MTG16-
downregulated targets
We previously demonstrated that AML1-MTG16 interacts
with both HDAC1 and HDAC3 [28]. Further, we found
that AML1-MTG16 can induce downregulation marked by
repressive histone hypoacetylation at the Csf1r chromatin
[19]. Here we show that, in A16 cells, the chromatin asso-
ciated with both the region containing the AML1-consen-
sus motif and the region encompassing the transcription
start site of Fcer1a, Tcfec, Ptprcap, F2rl3, and Mgmt (Figure
3A) displays a significant (p < 0.05) decrease of acetylated
histone H4 (Ac-H4), and a significant (p < 0.05) increase
of H3K9 tri-methylation (Tri-Met-H3-K9) (Figure 4A),
supporting the acquisition of a repressive chromatin state
[29-31].
Repressive histone modifications are often associated
with aberrant hypermethylation at CpG islands present in
the 5' regulatory regions of many genes [32,33] and refer-
ences within). By using the CpG island searcher [34], a
software for the identifying CpG islands, we could iden-
tify a CpG island only in the Mgmt promoter region [35]
(Figure 4B). Bisulfite sequencing analysis of this region
detected hypermethylation in AML1-MTG16-positive
cells (Figure 4B).
The overall epigenetic analysis indicates that downregula-
tion of AML1-targets by AML1-MTG16 can be achieved,
even in the absence of DNA methylation, when there is a
critical quantitative level of repressive histone changes.
Discussion
In this study we show the effectiveness of integrating glo-
bal gene expression array analysis with a bioinformatic
approach aimed at detecting AML1-consensus sequences
for identifying novel putative direct AML1-targets down-
regulated by AML1-MTG16 in 32D cells. Downregulation
of these genes is marked by a distinct repressive chromatin
profile.
When we surveyed the 37 most significantly downregu-
lated genes for the presence of the AML1-consensus
motif(s) in the 10 Kb region encompassing the transcrip-
tion start site, we closed on seventeen putative direct
AML1-MTG16 targets. For five of these genes, Fcer1a,
Tcfec, Ptprcap, F2rl3 and Mgmt, which were among the
most significantly downregulated, we were able to dem-
onstrate, using ChIP analysis, the binding of both AML1
and AML1-MTG16 to the gene regions containing the
AML1-motifs. Thus, our two-tier approach, combining
gene expression array analysis with bioinformatic survey
for transcription factor-consensus sequences, seems to be
a powerful strategy for identifying transcription factor tar-
gets, which would otherwise be missed when using con-
ventional gene expression array analysis alone.
The chromatin of the five downregulated genes, Fcer1a,
Tcfec, Ptprcap, F2rl3, and Mgmt, was marked not only by
significant levels of histone H4 hypoacetylation, but also
by significant levels of repressive histone H3-K9 trimeth-
ylation, suggesting that AML1-MTG16 might induce the
recruitment of both histone deacetylases [28] and histone
methyltransferases. Apparently, a critical quantity of
repressive histone modifications, even in the absence of
CpG methylation, might per se be sufficient to "lock in" a
transcriptionally downregulated state. In the case of
Mgmt, which has a CpG island, it is instead possible that
the accumulation of histone repressive changes preceded
CpG hypermethylation [[36], and references within].
It is noteworthy that all the genes for which we demon-
strated AML1-MTG16-induced epigenetic downregula-
tion encode for functions relevant to either hematopoiesis
and/or leukemogenesis. We would like to underline that
downregulation of two of the genes that we identified
might be relevant to AML1-MTG16-induced leukemogen-
esis. One of these genes is Tcfec, whose human counter-
part encodes a transcription factor that induces the
granulocyte colony stimulating factor receptor G-CSFR
[23,24]. Remarkably, Tcfec downregulation in A16 cells is
paralleled by a significant downregulation of G-csfr (data
not shown), indicating that AML1-MTG16 might have
triggered a coordinated cascade of transcriptional down-
regulation, as we observed in other differentiation model
systems [37,38]. The second gene is Mgmt, encoding the
DNA repair enzyme O6-Methylguanine-DNA-methyl-
transferase, which is frequently silenced and hypermethyl-
ated in leukemia [39]. MGMT epigenetic silencing is
thought to lead to random mutations in cancer [40]. A
recent study has shown that expression of different acute
myeloid leukemia fusion proteins, including AML1-
MTG8, leads to downregulation of several DNA repair
genes [41]. Thus, the induction of a "mutator phenotype"
might be a common consequence of leukemia fusion pro-
tein expression.
A few global gene expression studies on cells expressing
exogenous AML1-MTG8 have been recently described
[42-44]. Given the use of different cell systems, it is diffi-
cult to compare the differentially expressed genes in
AML1-MTG16-positive 32D cells with the differentially
expressed genes reported for AML1-MTG8. Nevertheless,
we could identify a few gene families (e.g. S100 Calcium-
binding proteins) that are similarly affected by both
AML1-MTG8 and AML1-MTG16 even in different cell
contexts. Extending our study to the comparison of the
epigenetic signatures imposed by either exogenous AML1-Page 11 of 16
(page number not for citation purposes)
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38
Page 12 of 16
(page number not for citation purposes)
Repressive epigenetic changes at the AML1-targetsFigure 4
Repressive epigenetic changes at the AML1-targets. A. ChIP with antibodies against either acetylated histone H4 or tri-
methylated histone H3 Lysine 9 (tri-Met-H3-K9) followed by quantitative PCR with primers amplifying a region encompassing 
either the transcription start site (+1) or the AML1-consensus detected a different level of repressive histone changes in all five 
genes in A16 cells. B. In silico analysis identified a CpG island only in the Mgmt promoter. This CpG island is hypermethylated in 
A16 cells (bottom, right).
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38MTG16 or exogenous AML1-MTG8 in the very same cell
context (e.g. 32D cells) might enable us to narrow down
additional critical epigenetic signatures consequent to
t(8;21) and t(16;21) translocations.
Conclusion
In this study, we show that AML1-MTG16, the leukemia
fusion protein associated with the non-random chromo-
some translocation t(16;21)(q24;q22), can impose tran-
scriptional downregulation marked by a distinct
epigenetic signature at specific AML1-target sites in the
genome. Thus, our findings further support the hypothe-
sis that non-random genetic abnormalities can lead to
non-random epigenetic changes in leukemia cells [19,45].
Methods
Cell cultures
Stable clones obtained from mouse myeloid 32D cells
infected either with pLNCX2-AML1-MTG16 (A16 clones)
or the empty vector pLNCX2 (mock clones) were previ-
ously described [19]. Two prototypic A16 clones and two
prototypic mock clones were used in this study. Cells were
maintained in the presence of 10 ng/ml of murine IL-3
(BD Biosciences, San Jose, CA, USA) in RPMI 1640
medium supplemented with 10% fetal calf serum, 1%
antibiotics (penicillin/streptomycin), adjusting the cell
density to 2 × 105 cells/ml daily. To induce granulocyte
differentiation, cells were washed in RPMI medium, and
IL-3 was replaced with 10 ng/ml human G-CSF (Amgen,
Thousand Oaks, CA, USA). Differentiation was micro-
scopically evaluated on cytospin preparations stained
with May-Grünwald-Giemsa.
RNA extraction and microarray hybridization
Total RNA was extracted with RNeasy mini kit (Qiagen,
Hilden, Germany) and treated with DNase (Qiagen).
Double stranded cDNA was generated from 5 µg RNA
using Superscript ds cDNA synthesis kit (Invitrogen,
Carlsbad, CA, USA) and T7-oligo(dT) primers. The cDNA
was purified with GeneChip Sample Cleanup Module
(Affymetrix, Santa Clara, CA, USA) and used to synthesize
biotin-labeled cRNA with Enzo RNA transcript Labeling
Kit (Enzo Life Science, Farmingdale, NY, USA). Purified
cRNA was quantified by spectrophotometric methods and
the concentration was adjusted in order to exclude the car-
ryover of unlabeled RNA. 11 µg of cRNA were then frag-
mented in fragmentation buffer (Affymetrix) at 95°C for
35 minutes and hybridized for 16 h at 45°C onto
MOE430A microarrays (Affymetrix). After washing and
staining, the chips were scanned in a Hewett-Packard/
Affymetrix scanner at 570 nm. For all the samples the 5'/
3' ratios of Gapdh were 0.7 – 0.9. In comparative experi-
ments the scaling factor, noise and presence calls were
similar. Gene expression data represent the average of two
independent experiments.
Microarray data analysis
The arrays were normalized by geometric mean intensity
for each probe set and scaled using log2 transformation
for further analysis. Comparison between the A16 and
mock clones grown with either IL-3 or G-CSF was done
using Spotfire Decision Site. This comparison generated a
p-value from a t-test to statistically extract significant
changes in mRNA expression levels between the groups.
p-values < 0.05 were considered significant. The null
hypothesis is that the samples between the groups are
derived from the same population i.e. there is no signifi-
cant differential expression. The t-test looks at the variance
within the groups as well as between them. To be consid-
ered significantly differentially expressed the variance had
to be greater between than within the groups to a level of
p < 0.05. Ratios were generated by dividing the average of
the unlogged control data by the average of the unlogged
AML1-MTG16 data. Ratios were then portrayed as positive
or negative fold change between A16 and mock. To con-
firm statistical significance of these ratios the differentially
expressed genes had to satisfy an arbitrary cut-off ratio as
well as having a p-value < 0.05 (see Results section). Anal-
ysis of the protein networks was performed by using Inge-
nuity Pathways Analysis (Ingenuity Systems, Redwood
City, CA), software able to identify molecular networks
based on known functional or physical interactions
among the proteins encoded by the differentially
expressed genes.
Search of AML1-consensus sequence in differentially 
expressed genes
The well-annotated genes differentially expressed in the
A16 clone versus the mock clone either in the presence of
IL-3 or G-CSF (p < 0.01 and absolute fold change >3) were
searched for the AML1-consensus sequence "5'-TG(T/
C)GGT-3"' in the 10 kb region surrounding the transcrip-
tion initiation sites (from -5000 bp to +5000 bp) using an
in-house built PERL script. A 400 bp sequence flanking
the potential AML1-binding sites (200 bp on each side)
was extracted and analyzed with MEME, which is a soft-
ware package to discover motifs in groups of related DNA
sequences [46], and with multiple sequence alignment to
test whether additional conserved motifs in the surround-
ing regions could be identified and to assess the sequence
conservation extending the potential AML1-binding sites.
Real-time RT-PCR
Total RNA was obtained using Trizol (Invitrogen), treated
with DNase I (Ambion, Austin, TX, USA), retrotranscribed
with SuperScript™ First-Strand Synthesis System (Invitro-
gen) and amplified by Real-time RT-PCR on an iCycler
(Bio-Rad, Hercules, CA, USA) by using iQ SYBR Green
Supermix (Bio-Rad) and primers specific for γ actin, F2rl3,
Fcer1a, Ptprcap, Tcfec, and Mgmt (Table 4). Transcript lev-
els of the genes of interest were quantitated by the Delta-Page 13 of 16
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Table 4: Primers used for real time RT-PCR, quantitative ChIP, and bisulfite sequencing.
Primer name Orientation Sequence
Real time PCR primers
γ-Actin sense 5'-GCCGGCTTACACTGCGCTTCTT-3'
antisense 5'-TTCTGGCCCATGCCCACCAT-3'
F2rl3 sense 5'-GCTTCTGATCCTGGCAGCATG-3'
antisense 5'-GTGTCACTGTCGTTGGCACAG-3'
Fcer1a sense 5'-CCCTTTCCTGCTATGGGAACA-3'
antisense 5'-GCAGCCAATCTTGCGTTACATT-3'
Ptprcap sense 5'-GGATGAAGAGGATGCAGAAGAT-3'
antisense 5'-CTGACTCCTATAGTGCAGTGAC-3'
Tcfec sense 5'-AGTCTAATGATCCTGATATGCGC-3'
antisense 5'-TCCTGAATCCGGAGCCTAAGC-3'
Mgmt sense 5'-GAACTTGGCAGAATGGCTGAG-3'
antisense 5'-GGTGATGGAGAGCAGGCAA-3'
ChIP primers
Ptprcap- AML1-consensus sense 5'-GTCCTGCAGCTGGTGTTTACAG-3'
antisense 5'-CTGGTCTCTGAGTGGCTGCA-3'
Ptprcap-transcription start sense 5'-GAGGTCTGACAAGTTAGCTGTA-3'
antisense 5'-ACCCTGTAACTCACTTCTCACT-3'
Tcfec- AML1-consensus sense 5'AGAGCTTGACTAGAATGGATTT-3'
antisense 5'-GGTGCAACCCATTCATGGCTT-3'
Tcfec-transcription start sense 5'-AGTCACACCACTGGAGTAGTTTT-3'
antisense 5'-CCCTCGTCTCATAACCTAAGCA-3'
Fcer1a- AML1-consensus sense 5'-GGCCACTGACTTCAGTGTGAA-3'
antisense 5'-TGCATTCCAGTTCTCTGCAAGA-3'
Fcer1a-transcription start sense 5'-AGGTGTCAGCTGAAGGTACAATA-3'
antisense 5'-CCCACCATGACACTCTCTAAAT-3'
F2rl3-AML1-consensus sense 5'-AGGGTGTCTCTCTGAATCTGGA-3'
antisense 5'-GGCAAGTCTGTTATCTCAGCAT-3'
F2rl3-transcription start sense 5'-TTGGAGGAAGGCTGGATTGTTAT-3'
antisense 5'-CCCATTGGGATCTGCTTGCTCA-3'
Mgmt-AML1-consensus sense 5'-GAGCTGCACACTGGGAAGATG-3'
antisense 5'-GTGTACCAGATGCTGTGCAGG-3'
Mgmt-basic promoter sense 5'-CAGTTTCAGGTCTGGAAGAAGAG-3'
antisense 5'-AGCTGTGGGCTTGTAGTCCGAG-3'
Control region sense 5'-ATGCAACACACAACAAAGCAAA-3'
antisense 5'-GGCCAAATGAGGTTGTGTCCT-3'
Bisulfite sequencing primers
Mgmt-CpG-1st PCR sense 5'-TAGTGATTGGATTTTTAGTGGGT-3'
antisense 5'-CTATCTCCCTAAACTTCAACTC-3'
Mgmt-CpG-2nd PCR sense 5'-GTGAGAAGGTGTAGTTTAGTTT-3'
antisense 5'-CTCACCAACTTACAAACTACAA-3'
BMC Genomics 2007, 8:38 http://www.biomedcentral.com/1471-2164/8/38delta Ct method, using the house keeping gene γ-actin for
normalization. The amplification efficiency, evaluated
from the sample slopes, was similar for all the samples
analyzed in the same experiment. Two independent
experiments were performed in triplicate using two mock
clones and two A16 clones. Significance was determined
by using the Student t-test.
Quantitative chromatin immunoprecipitation (ChIP)
ChIP was performed using reagents purchased from
Upstate (Charlottesville, VA, USA) following the manu-
facturer's protocol. AML1 and AML1-MTG16 binding was
assessed by ChIP with antibodies against either the AML1
C-terminus (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), or the MTG16 C-terminus [28], respectively. His-
tone hallmarks of repressive chromatin were assessed by
ChIP with antibodies against acetyl-histone H4 (Upstate)
and trimethyl-K9 at histone H3 (Upstate). Control ChIPs
were performed without the respective antibodies. The
immunoprecipitated DNA was amplified by real-time
PCR with primers specific for regions encompassing the
AML1-consensus, the transcription start site, or a control
region (Table 4). The DNA relative enrichment was calcu-
lated by using the Delta-delta Ct method. The PCR signals
obtained for each gene region were normalized to the PCR
signal obtained from the input DNA (total chromatin
fraction) and compared to a control region approximately
15 kb downstream of F2rl3 transcription start site. Two
independent experiments were performed in triplicate,
and significance was calculated by using the Student t-test.
Bisulfite sequencing
Genomic DNA was extracted with DNAzol (Invitrogen)
according to the manufacturer's instructions. DNA was
modified by sodium bisulfite treatment as previously
described [47]. Mgmt CpG island was amplified by nested
PCR by using the primers indicated in Table 4. The PCR
fragments were subcloned into pGEM-T (Promega, San
Luis Obispo, CA, USA) and 20 clones for each PCR frag-
ment were sequenced.
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